EUVIMEDEUVIMED entdecken
Crossref

Activated hepatic stellate cell membrane-camouflaged nanomedicine enables targeted HDAC6 inhibition for liver fibrosis therapy

Lin Yu, Lu Zhang, Lulu Gao, Siyue Huang, Xueying Qin, Zirui Wang, Siqi Li, Chunyan Mei, Maolin Zhang, Yaojing Zhang, Wei Wang, Min Wu und 1 weitere

Journal of Controlled Release · 2026-08 · 396 · 115100

DOI: 10.1016/j.jconrel.2026.115100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Controlled Release, 2026-08. Verfasst von Lin Yu und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, PR China; Department of Radiol…. Hauptthemen laut MEDLINE: Hepatic Stellate Cells, Histone Deacetylase 6, Liver Cirrhosis, Histone Deacetylase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 65 Literaturangaben. Gefördert von: Graduate Research and Innovation Projects of Jiangsu Province, Natural Science Foundation of Yangzhou Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a common outcome of chronic liver injury and can progress to cirrhosis, yet effective anti-fibrotic therapies remain limited. Here, we identify histone deacetylase 6 (HDAC6) as the most consistently upregulated zinc-dependent HDAC in fibrotic livers and activated hepatic stellate cells (HSCs). However, systemic HDAC6 inhibition may be constrained by inefficient delivery to fibrogenic HSCs and increased off-target exposure. To enable selective HDAC6 inhibition in activated HSCs, we developed an activated HSC membrane-camouflaged PLGA nanomedicine (PLGA-Ric@HSCM) loaded with the HDAC6 inhibitor ricolinostat (Ric). Membrane cloaking preserves key adhesion and recognition proteins, promotes homotypic uptake by HSCs, and reduces macrophage sequestration in vivo. PLGA-Ric@HSCM dampened profibrotic transcriptional programs by restoring microtubule acetylation and suppressing both the canonical TGFβ/Smad2/3 pathway and the p38/c-JUN/ATF2 axis. Compared to PLGA-Ric, PLGA-Ric@HSCM shows a more pronounced reduction in fibrosis burden and improved hepatic pathology across etiologically distinct models. Together, PLGA-Ric@HSCM provides a biomimetic, HSC-targeted strategy to reprogram acetylation homeostasis via HDAC6 inhibition and consequently mitigate liver fibrogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatic Stellate CellsHistone Deacetylase 6Liver CirrhosisHistone Deacetylase InhibitorsHydroxamic AcidsAnimalsHumansPolylactic Acid-Polyglycolic Acid CopolymerNanomedicineMaleMice, Inbred C57BLCell MembraneNanoparticlesMicePyrimidines

Stichwörter der Autor:innen

HDAC6Hepatic stellate cellsLiver fibrosisNanoparticlesTargeted therapy

Substanzen

Histone Deacetylase 6Histone Deacetylase InhibitorsHydroxamic AcidsricolinostatPolylactic Acid-Polyglycolic Acid CopolymerPyrimidines

Autor:innen und Institutionen

  • School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, PR China; Department of Radiology, Affiliated Hospital of Yangzhou University, Yangzhou University,…
  • School of Basic Medical Sciences & School of Public Health, Faculty of Medicine, Yangzhou University, Yangzhou 225009, PR China; The First School of Clinical Medicine, Faculty of Medicine, Yangzhou University, Yangzhou…
  • The First School of Clinical Medicine, Faculty of Medicine, Yangzhou University, Yangzhou 225009, PR China.
  • School of Traditional Chinese Medicine, Faculty of Medicine, Yangzhou University, Yangzhou 225009, PR China.
  • Department of Radiology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou 225001, PR China.
  • Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou 225001, PR China.

Förderung

  • Graduate Research and Innovation Projects of Jiangsu Province
  • Natural Science Foundation of Yangzhou Municipality
  • National Natural Science Foundation of China
  • China Academy of Space Technology
  • Yangzhou University
  • Government of Jiangsu Province

Zitieren

APA

Yu, L., Zhang, L., Gao, L., Huang, S., Qin, X., Wang, Z., Li, S., Mei, C., Zhang, M., Zhang, Y., Wang, W., Wu, M., & Liu, J. (2026). Activated hepatic stellate cell membrane-camouflaged nanomedicine enables targeted HDAC6 inhibition for liver fibrosis therapy. Journal of Controlled Release, 396, 115100. https://doi.org/10.1016/j.jconrel.2026.115100

Vancouver

Yu L, Zhang L, Gao L, Huang S, Qin X, Wang Z, et al. Activated hepatic stellate cell membrane-camouflaged nanomedicine enables targeted HDAC6 inhibition for liver fibrosis therapy. Journal of Controlled Release. 2026;396:115100. doi:10.1016/j.jconrel.2026.115100

BibTeX
@article{Yu2026,
  author = {Yu, Lin and Zhang, Lu and Gao, Lulu and Huang, Siyue and Qin, Xueying and Wang, Zirui and Li, Siqi and Mei, Chunyan and Zhang, Maolin and Zhang, Yaojing and Wang, Wei and Wu, Min and Liu, Jingjing},
  title = {Activated hepatic stellate cell membrane-camouflaged nanomedicine enables targeted HDAC6 inhibition for liver fibrosis therapy},
  journal = {Journal of Controlled Release},
  year = {2026},
  volume = {396},
  pages = {115100},
  doi = {10.1016/j.jconrel.2026.115100}
}
Kostenlos starten →